
D&D Pharmtech scores US patent for MASH drug candidate DD01
D&D Pharmatech, a Korean developer of GLP-1-based therapeutics, announced Tuesday that it has secured a U.S. patent for DD01, its investigational treatment for metabolic-associated steatohepatitis (MASH). DD01, a long-acting GLP-1/glucagon dual …